All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS

Adrian Vallejo; Karmele Valencia; Silvestre Vicent

doi:10.1080/23723556.2017.1314239

All for one and FOSL1 for all: FOSL1 at the crossroads of lung and pancreatic cancer driven by mutant KRAS

Mol Cell Oncol. 2017 Apr 5;4(3):e1314239. doi: 10.1080/23723556.2017.1314239. eCollection 2017.

Authors

Adrian Vallejo^{1

2}, Karmele Valencia¹, Silvestre Vicent^{1

2

3}

Affiliations

¹ Program in Solid Tumors and Biomarkers, Center for Applied Medical Research, Universidad de Navarra, Pamplona, Spain.
² Department of Histology and Pathology, University of Navarra, Pamplona, Spain.
³ IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.

Abstract

KRAS proto-oncogene, GTPase (KRAS) remains refractory to current therapies. We devised an integrative cross-tumor approach to expose common core elements up-regulated in mutant KRAS cancers that could provide new treatment opportunities. This approach identified FOSL1 (Fos-like antigen 1) as a clinically and functionally relevant gene in mutant KRAS-driven lung and pancreatic cancers, and unveiled downstream transcriptional targets amenable to pharmacological inhibition.

Keywords: FOSL1; KRAS oncogene; gene signature; lung cancer; mouse genetics; pancreatic cancer; pharmacological inhibitors.